Alnylam Pharmaceuticals
ALNY
#1123
Rank
C$29.91 B
Marketcap
C$223.36
Share price
3.42%
Change (1 day)
-63.94%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$28.10

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$28.22. In 2025 the company made an earnings per share (EPS) of C$2.51.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$28.101020.95%
2025C$2.51
2023C-$5.03-62%
2022C-$13.2329.03%
2021C-$10.26-3.36%
2020C-$10.61-8.48%
2019C-$11.597.67%
2018C-$10.7739.74%
2017C-$7.7112.94%
2016C-$6.8238.84%
2015C-$4.91-32.88%
2014C-$7.32259.44%
2013C-$2.04-31.25%
2012C-$2.96

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$7.48-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$2.82-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$66.92 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.75-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.04-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.27-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$0.64-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C-$4.74-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA